VCBeat Health
Contact Us
Home
China Healthcare Select
Insights
MNC China Lens
Vertical Industries
Services
Partnership Development
Market Entry Advisory
Ecosystem Engagement Advisory
About VCBeat
Why VCBeat
Log In
Home
Taiji Group (600129.SH) Announces NMPA Approval for Clinical Trials of DSC158A Tablets, a Novel RNA Polymerase Inhibitor for Influenza A and B
Taiji Group (600129.SH) Announces NMPA Approval for Clinical Trials of DSC158A Tablets, a Novel RNA Polymerase Inhibitor for Influenza A and B
May 18, 2026 15:37 CST Updated May 19, 10:41
Share:
